Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regeneron Pharmaceuticals (NQ: REGN )

725.05 +0.05 (+0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 750,770
Open 725.00
Bid (Size) 716.00 (1)
Ask (Size) 724.95 (2)
Prev. Close 725.00
Today's Range 719.00 - 726.77
52wk Range 538.01 - 837.55
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71%
 
Via Benzinga
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+0.64%
+0.64%
1 Month
-9.57%
-9.57%
3 Month
-4.32%
-4.32%
6 Month
-2.22%
-2.22%
1 Year
+9.07%
+9.07%

More News

Read More
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals Unusual Options Activity For May 25
Via Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
Via Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 5/19 Morning Trading
Via Investor Brand Network
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
A Good Week For The Market But A Pause In The Biotech Rally
Via Talk Markets
Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained
Via Benzinga
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
Via Benzinga
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The 7 Growth Stocks You Need to Own Now for Maximum Returns
Via InvestorPlace
AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market
Via Benzinga
Why Regeneron Pharmaceuticals Stock Is Tanking Today
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Cathie Wood Stocks That Can Get You Through Any Recession
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Via MarketBeat
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today
Via Benzinga
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.